Tag: immunotherapy

Search News
Categories
Archives
Research highlighted in ASCO annual report on progress against cancer

2nd February 2021

Research led by Professors Peter Schmid and Thomas Powles from Barts Cancer Institute, Queen Mary University of London, has been selected by the American Society of Clinical Oncology (ASCO) for inclusion in the Clinical Cancer Advances 2021, the Society’s annual review of progress against cancer. The notable studies, which investigated the use of immunotherapy in the treatment of triple negative breast cancer and advanced bladder cancer, are featured as two of many remarkable milestones in clinical cancer research and care.

Read more

CAR T cell therapy for pancreatic cancer

22nd January 2021

Researchers from Barts Cancer Institute, Queen Mary University of London, have identified a protein that may represent a novel therapeutic target for the treatment of pancreatic cancer. Using this protein as a target, the team successfully created a CAR T cell therapy – a type of immunotherapy – that killed pancreatic cancer cells in a pre-clinical model.

Read more

Novel insights into graft-versus-host disease

13th October 2020

Research led by Barts Cancer Institute, Queen Mary University of London, has identified a subset of immune cells involved in site-specific tissue damage in cancer patients who have developed harmful graft-versus-host disease after stem cell transplantation. The insights gained from the study may help to define new targets for more selective approaches to prevent or treat this condition in patients who have received a stem cell transplant.

Read more

Immune ‘cloaking’ in cancer cells

14th September 2020

Researchers have created a mathematical model that can determine the impact of the immune system on tumour evolution. The information gained from using this model may be able to be used to predict whether immunotherapy is likely to be effective for a patient’s cancer, helping to guide treatment decisions.

Read more

KEYNOTE-522: Immune therapy for breast cancer

30th September 2019

Results of an interim analysis from the KEYNOTE-522 trial have shown a treatment combination of immunotherapy plus chemotherapy to improve response rates in patients with early triple-negative breast cancer. Prof Peter Schmid presented the results at the ESMO Congress 2019 in Barcelona, Spain.

Read more

CRUK Career Establishment Award

4th July 2019

Dr Oliver Pearce has received a Cancer Research UK Career Establishment Award, which will fund a project that will look at restoring response to immunotherapy in triple-negative breast cancer.

Read more

Search News
Categories
Archives